GHDX : Summary for Genomic Health, Inc. - Yahoo Finance

U.S. Markets open in 9 hrs 24 mins

Genomic Health, Inc. (GHDX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.99+0.30 (+0.95%)
At close: 4:00PM EDT
People also watch
LMNXQGENFMIACORSGEN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close31.69
Open31.77
Bid24.30 x 100
Ask0.00 x
Day's Range31.34 - 32.52
52 Week Range23.57 - 33.96
Volume62,320
Avg. Volume129,655
Market Cap1.09B
Beta0.69
PE Ratio (TTM)-76.17
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire16 hours ago

    Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients

    REDWOOD CITY, Calif., March 29, 2017 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ (GPS) is a strong independent predictor of metastases at 10 years in prostate cancer patients across all National Comprehensive Cancer Network (NCCN) clinical risk groups. The clinical validation study data were designated one of the "best posters" (abstract #352) at the 32nd Annual European Association of Urology (EAU) Congress in London. "Now validated for all major near- and late-term endpoints of adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death, Oncotype DX becomes the only genomic test to provide physicians with an assessment of both the current state and future risk of their patient's cancer based on biology to help them confidently decide between active surveillance or surgery," said Phil Febbo, M.D., chief medical officer, Genomic Health.

  • PR Newswire6 days ago

    Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results

    REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast Recurrence Score® in guiding chemotherapy treatment decisions in certain node-positive patients. Consistent with previously published findings in Nature Partner Journals Breast Cancer, the new SEER Registries analysis demonstrates that breast cancer patients with limited node-positive disease who have low Breast Recurrence Score™ (RS) results have an excellent chance of breast cancer-specific survival (BCSS). These data, along with results from 14 additional Oncotype DX® studies in breast cancer patients, were also presented at the 15th St. Gallen International Breast Cancer Conference in Vienna.

  • Genomic Health's Cancer Test Business Strong, Expenses High
    Zacks8 days ago

    Genomic Health's Cancer Test Business Strong, Expenses High

    On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.